ARTICLE | Company News
Mero licenses AAT deficiency candidate from AstraZeneca
December 8, 2017 2:53 AM UTC
AstraZeneca plc (LSE:AZN; NYSE:AZN) granted Mereo BioPharma Group plc (LSE:MPH) an exclusive license and option to acquire AZD9668, an oral inhibitor of neutrophil elastase (ELANE; NE; HLE) which is...